Nang Kuang Pharmaceutical Bilan de santé

Santé financière contrôle des critères 5/6

Nang Kuang Pharmaceutical possède un total de capitaux propres de NT$2.3B et une dette totale de NT$508.8M, ce qui porte son ratio d'endettement à 21.8%. Son actif total et son passif total sont NT$3.5B et de NT$1.2B. L'EBIT de Nang Kuang Pharmaceutical est NT$205.3M ce qui fait que son ratio de couverture des intérêts 576.8. Elle dispose de liquidités et de placements à court terme de NT$229.5M.

Informations clés

21.8%

Ratio d'endettement

NT$508.75m

Dette

Ratio de couverture des intérêts	576.8x
Argent liquide	NT$229.47m
Fonds propres	NT$2.33b
Total du passif	NT$1.21b
Total des actifs	NT$3.54b

Mises à jour récentes de la santé financière

Nang Kuang Pharmaceutical (GTSM:1752) Has A Pretty Healthy Balance Sheet

Mar 20

Recent updates

There May Be Some Bright Spots In Nang Kuang Pharmaceutical's (TWSE:1752) Earnings

Nov 19

Nang Kuang Pharmaceutical Co., Ltd.'s (TWSE:1752) 28% Price Boost Is Out Of Tune With Earnings

May 22

Some Investors May Be Willing To Look Past Nang Kuang Pharmaceutical's (TWSE:1752) Soft Earnings

Apr 02

Nang Kuang Pharmaceutical (GTSM:1752) Has A Pretty Healthy Balance Sheet

Mar 20

Should You Or Shouldn't You: A Dividend Analysis on Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)

Mar 03

Declining Stock and Decent Financials: Is The Market Wrong About Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)?

Feb 13

Nang Kuang Pharmaceutical's (GTSM:1752) Stock Price Has Reduced 17% In The Past Five Years

Jan 26

Estimating The Fair Value Of Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)

Jan 08

Here's How We Evaluate Nang Kuang Pharmaceutical Co., Ltd.'s (GTSM:1752) Dividend

Nov 29

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 1752 ( NT$1.4B ) dépassent ses passifs à court terme ( NT$1.1B ).

Passif à long terme: Les actifs à court terme de 1752 ( NT$1.4B ) dépassent ses passifs à long terme ( NT$91.4M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de 1752 ( 12% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de 1752 est passé de 21.4% à 21.8% au cours des 5 dernières années.

Couverture de la dette: La dette de 1752 est bien couverte par le flux de trésorerie opérationnel ( 85.9% ).

Couverture des intérêts: Les paiements d'intérêts de 1752 sur sa dette sont bien couverts par l'EBIT ( 576.8 x couverture).

Nang Kuang Pharmaceutical Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Nang Kuang Pharmaceutical (GTSM:1752) Has A Pretty Healthy Balance Sheet

Recent updates

There May Be Some Bright Spots In Nang Kuang Pharmaceutical's (TWSE:1752) Earnings

Third quarter 2024 earnings released: EPS: NT$0.58 (vs NT$0.46 in 3Q 2023)

Nang Kuang Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Nov 08, 2024

Second quarter 2024 earnings released: EPS: NT$0.44 (vs NT$0.92 in 2Q 2023)

Nang Kuang Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Aug 07, 2024

Upcoming dividend of NT$2.00 per share

Nang Kuang Pharmaceutical Co., Ltd. Declares Cash Dividends, Payable on July 31, 2024

Nang Kuang Pharmaceutical Co., Ltd.'s (TWSE:1752) 28% Price Boost Is Out Of Tune With Earnings

Investor sentiment improves as stock rises 24%

First quarter 2024 earnings released: EPS: NT$0.54 (vs NT$0.93 in 1Q 2023)

Nang Kuang Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on May 02, 2024

Nang Kuang Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on May 02, 2024

Some Investors May Be Willing To Look Past Nang Kuang Pharmaceutical's (TWSE:1752) Soft Earnings

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: NT$1.96 (vs NT$3.49 in FY 2022)

Nang Kuang Pharmaceutical Co., Ltd., Annual General Meeting, Jun 18, 2024

Nang Kuang Pharmaceutical Co., Ltd. Appoints Pen-Sung Chen as Corporate Governance Officer

Nang Kuang Pharmaceutical Co., Ltd. Announces Resignation of Wen-Yung Tsai as Spokesperson, Financial Officer, Accounting Officer and Corporate Governance Officer

Nang Kuang Pharmaceutical Co., Ltd. Provides Update on the Patent Infringement

Third quarter 2023 earnings released: EPS: NT$0.46 (vs NT$0.74 in 3Q 2022)

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: NT$0.92 (vs NT$0.74 in 2Q 2022)

Upcoming dividend of NT$2.30 per share at 3.6% yield

Investor sentiment improves as stock rises 19%

Full year 2022 earnings released: EPS: NT$3.49 (vs NT$1.94 in FY 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Nang Kuang Pharmaceutical Co., Ltd. Appoints Wen-Yung Tsai as Corporate Governance Officer

Second quarter 2022 earnings released: EPS: NT$0.74 (vs NT$0.54 in 2Q 2021)

Upcoming dividend of NT$1.80 per share

Nang Kuang Pharmaceutical Co., Ltd. Receives Final U.S. FDA Approval for Its ANDA

First quarter 2022 earnings released: EPS: NT$0.41 (vs NT$0.44 in 1Q 2021)

Nang Kuang Pharmaceutical Co., Ltd., Annual General Meeting, May 27, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: EPS NT$0.45 (vs NT$0.29 in 3Q 2020)

Upcoming dividend of NT$1.60 per share

Second quarter 2021 earnings released: EPS NT$0.54 (vs NT$0.43 in 2Q 2020)

Full year 2020 earnings released: EPS NT$1.82 (vs NT$2.17 in FY 2019)

Nang Kuang Pharmaceutical (GTSM:1752) Has A Pretty Healthy Balance Sheet

Nang Kuang Pharmaceutical Co., Ltd., Annual General Meeting, May 27, 2021

Full year 2020 earnings released: EPS NT$1.82 (vs NT$2.17 in FY 2019)

Revenue misses expectations

Should You Or Shouldn't You: A Dividend Analysis on Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)

Declining Stock and Decent Financials: Is The Market Wrong About Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)?

Nang Kuang Pharmaceutical Co., Ltd. Receives U.S. Food and Drug Administration Tentative Approval for Abbreviated New Drug Application

Nang Kuang Pharmaceutical's (GTSM:1752) Stock Price Has Reduced 17% In The Past Five Years

New 90-day low: NT$37.60

Estimating The Fair Value Of Nang Kuang Pharmaceutical Co., Ltd. (GTSM:1752)

New 90-day high: NT$41.95

Nang Kuang Pharmaceutical Co., Ltd. Receives Final U.S. FDA Approval for its ANDA

Here's How We Evaluate Nang Kuang Pharmaceutical Co., Ltd.'s (GTSM:1752) Dividend

Third quarter 2020 earnings released: EPS NT$0.29

Revenue misses expectations

New 90-day low: NT$38.85

New 90-day low: NT$41.05

First half earnings released

New 90-day low - NT$41.50

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines